Bevacizumab Treatment for Vestibular Schwannoma in a Patient with Neurofibromatosis Type 2: Hearing Improvement and Tumor Shrinkage

2015 ◽  
Vol 101 (6) ◽  
pp. e167-e170 ◽  
Author(s):  
Andrea P. Sponghini ◽  
Francesca Platini ◽  
David Rondonotti ◽  
Riccardo Soffietti
Keyword(s):  
Vestibular Schwannoma ◽  
Neurofibromatosis Type ◽  
Neurofibromatosis Type 2 ◽  
Tumor Shrinkage ◽  
Hearing Improvement ◽  
Bevacizumab Treatment

Bevacizumab for Hearing Preservation in Neurofibromatosis Type 2: Emphasis on Patient-Reported Outcomes and Toxicities

2018 ◽  
Vol 160 (3) ◽  
pp. 526-532 ◽  
Author(s):  
Pavlina Sverak ◽  
Meredith E. Adams ◽  
Stephen J. Haines ◽  
Samuel C. Levine ◽  
David Nascene ◽  
...  
Keyword(s):  
Patient Reported Outcomes ◽  
Tumor Volume ◽  
Neurofibromatosis Type ◽  
Hearing Preservation ◽  
Neurofibromatosis Type 2 ◽  
Hearing Improvement ◽  
Radiographic Response ◽  
Bevacizumab Treatment ◽  
Patient Reported

Objective Bevacizumab for hearing preservation in patients with neurofibromatosis type 2 (NF2) is an emerging practice. We set out to characterize the effectiveness and toxicity of bevacizumab in our patient group. Study Design Case series with chart review. Setting Tertiary referral center. Subjects and Methods Seventeen consecutive patients with NF2 received bevacizumab treatment for vestibular schwannomas, including 2 patients treated to maintain cochlear implant performance. Volumetric analysis of serial magnetic resonance imaging scans was used to evaluate radiographic response, and hearing response was evaluated with serial audiograms. Patient-reported outcomes were also assessed, including subjective hearing improvement, changes in tinnitus, vertigo, headaches, ear pain, and improvement in ability to communicate via telephone. Results A positive radiographic response occurred in 8 of 17 (47%) patients and the median tumor volume change was a tumor decrease of 19%. A positive hearing response was recorded in 5 of 9 (56%) patients. Two patients had a word recognition score improvement over 40%. There was an approximately 40% improvement in patient-reported outcomes. Primary toxicities included hypertension, proteinuria, dysgeusia, and amenorrhea. Conclusion Bevacizumab treatment was followed by hearing improvement in 56% of patients, while decreased tumor volume was noted in 47%. These outcomes agree favorably with prior reported series. There were significant improvements in patient-reported outcomes that have not been described previously.

scholarly journals Contextualizing the Modern Epidemiology of Neurofibromatosis Type 2 in an Era of Heightened Detection of Sporadic Vestibular Schwannoma

2020 ◽  
Vol 41 (4) ◽  
pp. e501-e506 ◽  
Author(s):  
Eric M. Dowling ◽  
John P. Marinelli ◽  
Christine M. Lohse ◽  
Matthew L. Carlson
Keyword(s):  
Vestibular Schwannoma ◽  
Neurofibromatosis Type ◽  
Neurofibromatosis Type 2

Cochlear Implantation in Patients with Neurofibromatosis Type 2 and Bilateral Vestibular Schwannoma

2006 ◽  
Vol 27 (4) ◽  
pp. 512-518 ◽  
Author(s):  
Lawrence R. Lustig ◽  
Jennifer Yeagle ◽  
Colin L. W. Driscoll ◽  
Nikolas Blevins ◽  
Howard Francis ◽  
...  
Keyword(s):  
Vestibular Schwannoma ◽  
Cochlear Implantation ◽  
Neurofibromatosis Type ◽  
Neurofibromatosis Type 2

Radiotherapy in Patients with Vestibular Schwannoma and Neurofibromatosis Type 2: Clinical Results and Review of the Literature

2014 ◽  
Vol 100 (2) ◽  
pp. 189-194 ◽  
Author(s):  
Johanna Wagner ◽  
Thomas Welzel ◽  
Daniel Habermehl ◽  
Jürgen Debus ◽  
Stephanie E Combs
Keyword(s):  
Vestibular Schwannoma ◽  
Neurofibromatosis Type ◽  
Clinical Results ◽  
Neurofibromatosis Type 2 ◽  
Review Of The Literature

scholarly journals Combined translabyrinthine, anterior petrosal approach for resection of collision vestibular schwannoma and petrous apex meningioma in neurofibromatosis type 2, with auditory brainstem implant placement

2021 ◽  
Vol 5 (2) ◽  
pp. V17
Author(s):  
Usman A. Khan ◽  
Jillian H. Plonsker ◽  
Rick A. Friedman ◽  
Marc S. Schwartz
Keyword(s):  
Vestibular Schwannoma ◽  
Neurofibromatosis Type ◽  
Auditory Brainstem ◽  
Neurofibromatosis Type 2 ◽  
Petrous Apex ◽  
Surgical Decision ◽  
Implant Placement ◽  
History Of ◽  
Sporadic Tumors

The natural history of neurofibromatosis type 2 (NF2) is profound bilateral hearing loss. The decision to pursue microsurgery may be more complicated in NF2 than with sporadic tumors. Schwannomas in NF2 often occur with other skull base tumors. Treatment should be tailored to preserve auditory perception for as long as possible. The authors present the case of a man with NF2 and a vestibular schwannoma who has poor hearing on the same side as a large petrous apex meningioma, both opposite to a well-hearing ear. This case highlights surgical decision-making and technical nuances during resection of collision tumors in NF2. The video can be found here: https://stream.cadmore.media/r10.3171/2021.7.FOCVID21130

scholarly journals The Effect of Bevacizumab on Vestibular Schwannoma Related to Neurofibromatosis Type 2

2021 ◽  
Vol 31 (1) ◽  
pp. 5-14
Author(s):  
Simone Ardern-Holmes ◽  
Cassandra White ◽  
Sarita Bahure ◽  
Simon So ◽  
Geoff McCowage ◽  
...  
Keyword(s):  
Vestibular Schwannoma ◽  
Neurofibromatosis Type ◽  
Neurofibromatosis Type 2

Endoglin (CD105) expression in neurofibromatosis type 2 vestibular schwannoma

Head & Neck ◽  
2019 ◽  
Vol 41 (10) ◽  
pp. 3612-3617 ◽  
Author(s):  
Gino Marioni ◽  
Lorenzo Nicolè ◽  
Diego Cazzador ◽  
Chiara Pavone ◽  
Domenico D'Avella ◽  
...  
Keyword(s):  
Vestibular Schwannoma ◽  
Neurofibromatosis Type ◽  
Neurofibromatosis Type 2
Sign in / Sign up

Export Citation Format

Share Document